GRC-54276 is under clinical development by Ichnos Glenmark Innovation and currently in Phase II for Cervical Cancer. According to GlobalData, Phase II drugs for Cervical Cancer have a 35% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how GRC-54276’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

GRC-54276 overview

GRC-54276 is under development for the treatment of Hodgkin's lymphoma, non-Hodgkin lymphoma, solid tumor and breast cancer, cervical cancer, colon cancer and  ovarian cancer. It is administered through oral route. The drug candidate targets MAP4K1. It is developed based on Antigen Presenting Cell (APC) biology platform.

Ichnos Glenmark Innovation overview

Ichnos Glenmark Innovation specializes in research and development of novel cutting-edge therapeutics for the treatment of cancer. The company is headquartered in New York City, New York, the US.

For a complete picture of GRC-54276’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.